EPIRUS Biopharmaceuticals Joins Biosimilars Forum to Help Educate Patients and Healthcare Providers on Importance of Biosimil...
05 Novembre 2015 - 2:00PM
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical
company focused on the global development and commercialization of
biosimilar monoclonal antibodies (mAbs), and the Biosimilars Forum,
a not-for-profit organization of 12 leading companies representing
the U.S. biosimilars industry, today announced that EPIRUS has
joined the Forum.
The members of the Biosimilars Forum
collectively represent the largest pipeline of biosimilars in
development in the U.S. The Forum is also the first nonprofit
organization solely dedicated to expanding patient access to
biosimilars in the United States. The Forum currently includes:
Allergan, Amgen, Boehringer Ingelheim, Coherus Biosciences, EMD
Serono, Merck, Pfizer, Samsung Bioepis, Sandoz, Teva and now
EPIRUS.
“It’s an honor to join the Biosimilars Forum,
whose mission is to educate and advocate for public policies and
practices that encourage access, awareness and adoption of
biosimilars in the U.S.,” said Amit Munshi, President and Chief
Executive Officer, EPIRUS Biopharmaceuticals. “We intend to
leverage our global market expertise as we work collectively with
our industry peers to educate patients and physicians on the value
biosimilars represent to society as a whole.”
After the recent FDA approval of the first
biosimilar in the U.S. and the ongoing development and production
of other biosimilars, the founding members of the Biosimilars Forum
recognized the need for a sustained and unbiased biosimilars
education and advocacy program in the U.S. To this end, the
development of an independent nonprofit forum to raise awareness of
biosimilars and serve as a credible resource for information was
warranted. The Biosimilars Forum provides an opportunity for
companies developing biosimilars focused on the U.S. market to work
together and with other key stakeholders on topics instrumental to
biosimilars and patient care.
“We’re pleased to welcome EPIRUS to the
Biosimilars Forum and applaud their shared goal with our current
members to expand access and availability of biological medicines
and to improve healthcare delivery in the U.S.,” said Juliana Reed,
President, Biosimilars Forum. “EPIRUS’ robust pipeline and
experience in the global biosimilars market will be a great
contribution in our collective effort and common mission of
providing more consistent access to biological medicines at a lower
cost burden to physicians, and patients and their families.”
About EPIRUS
Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a
biopharmaceutical company focused on the global development and
commercialization of biosimilar monoclonal antibodies (mAbs).
EPIRUS’ goal is to improve global patient access to important,
cost-effective medicines. EPIRUS' current pipeline of biosimilar
product candidates includes: BOW015 (infliximab, reference biologic
Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070
(tocilizumab, reference biologic Actemra®); BOW080 (eculizumab,
reference biologic Soliris®); BOW090 (ustekinumab, reference
biologic STELARA®); and BOW100 (golimumab, reference biologic
SIMPONI®)i. The reference products for these candidates together
generated approximately $29.2 billion in global sales for 2014,
according to EvaluatePharma®. EPIRUS has established multiple
partnerships to support its regulatory and commercialization
efforts in global markets. For more information visit EPIRUS’
website at www.epirusbiopharma.com.
About the Biosimilars Forum
The Biosimilars Forum is a nonprofit
organization whose mission is to advance biosimilars in the United
States with the intent of expanding access and availability of
biological medicines, and improving health care. The founding
members of the Biosimilars Forum represent the majority of
companies with the most significant U.S. biosimilars development
portfolios.
To learn more about biosimilars, the Forum, and
how to get involved, visit BiosimilarsForum.org or go to
@USBiosimilars to follow related conversations and join the
dialogue.
i Remicade is a registered trademark of Johnson and Johnson
(www.jnj.com); Humira is a registered trademark of AbbVie
(www.abbvie.com); Actemra is a registered trademark of Chugai
Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group
(www.gene.com); Stelara is owned and marketed by Centocor Ortho
Biotech Inc, a wholly owned subsidiary of Johnson and Johnson
(www.jnj.com); Simponi is marketed by Janssen Biotech Inc
(www.janssenbiotech.com); Soliris is a registered trademark of
Alexion Pharmaceuticals, Inc. (www.alxn.com)
Contact Information:
EPIRUS
For media inquiries:
Mike Devine, FleishmanHillard
+1-212-453-2324
michael.devine@fleishman.com
For investor inquiries:
Tom Shea, EPIRUS Biopharmaceuticals
+1-617-600-3471
tshea@epirusbiopharma.com
Biosimilars Forum
For media inquiries:
Lynn Blenkhorn
508-851-0930
biosimilars@fkhealth.com
Aimee Steel
202-828-1895
Aimee.steel@hklaw.com
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024